BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:41 PM
 | 
Mar 02, 2009
 |  BC Extra  |  Clinical News

Nektar's NKTR-118 meets endpoint

Nektar (NASDAQ:NKTR) ended early a double-blind Phase II trial of NKTR-118 to treat opioid-bowel dysfunction, including opioid-induced constipation, after top-line data showed that two...

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >